PharmaCielo (PCLOF) Stock Analysis — October 2026

PharmaCielo (PCLOF) stock is currently trading at $0.0411 per share on the OTC exchange. This represents a daily gain of 0.00% ($0.00) from the previous closing price of $0.0411. Over the past 52 weeks, PCLOF has traded between a low of $0.0037 and a high of $0.12, placing the current price at approximately -65% from its annual high. The stock has a market capitalization of $7.5M, making it a notable cannabis companies tracked by Cannabismarketcap. PharmaCielo operates in the CBD sector, serving the broader cannabis industry.

PharmaCielo (PCLOF) has a current market capitalization of $7.5M, calculated by multiplying its 188.0M shares outstanding by the current stock price of $0.0411. Market capitalization is a key measure of a company's total equity value as perceived by the public market, and it places PharmaCielo among the small-cap cannabis companies tracked on Cannabismarketcap. Investors often use market cap alongside revenue and profitability metrics to assess relative valuation within the cannabis sector.

PharmaCielo (PCLOF) reports several important financial metrics that investors track closely. The company has a market capitalization of $7.5M. Cash and debt figures for PharmaCielo are not reported in our data. With 188.0M shares outstanding, investors should consider both the fundamental financial performance and share structure when evaluating PCLOF.

PharmaCielo trades under the ticker symbol PCLOF on the OTC exchange, and the stock is denominated in US dollars (USD). Shares can typically be purchased through most standard brokerage accounts, though some brokers may charge additional fees for OTC-listed securities. The stock sees average daily trading volume of approximately 0 shares, which is an important consideration for liquidity and the ability to enter or exit positions without significant price impact.

PharmaCielo is classified as a CBD and hemp company, meaning it specializes in cannabidiol (CBD) products derived from hemp, which are legal at the federal level under the 2018 Farm Bill. The CBD sector is a key segment of the cannabis market, and investors often compare companies within the same sector to identify relative outperformers. You can compare PCLOF with other CBD stocks on Cannabismarketcap's sector page to see how it ranks on metrics like market cap, revenue, and margins.

You can compare PharmaCielo (PCLOF) side-by-side with any cannabis stock on Cannabismarketcap using the dedicated comparison tool. Key comparison metrics include market cap ($7.5M). PharmaCielo sits in the CBD sector, so the most relevant peer comparisons would be against other CBD companies, though cross-sector comparisons can also reveal interesting insights about relative valuation. Visit the rankings page to see where PCLOF stands across all cannabis companies on metrics like revenue growth, cash position, and employee count (N/A).

PharmaCielo (PCLOF) has traded between a 52-week low of $0.0037 and a 52-week high of $0.12, with the current price of $0.0411 sitting approximately -65% from the annual high. This range represents a spread of $0.11 (3062% from low to high), which reflects the volatility the stock has experienced over the past year. The 52-week range is a commonly used technical indicator that helps investors understand whether a stock is trading near the top or bottom of its recent range, and it can inform decisions about entry and exit points. Cannabis stocks in general tend to exhibit higher volatility than broader market indices due to evolving regulations and market sentiment.

PharmaCielo (PCLOF) is valued at a market capitalization of $7.5M. In the cannabis industry, valuations can vary significantly depending on sector (MSO, LP, Ancillary, etc.), growth rate, and path to profitability. Investors can use the Cannabismarketcap rankings and comparison tools to benchmark PCLOF against specific competitors on valuation multiples, growth rates, and profitability.

Determining whether PharmaCielo (PCLOF) is overvalued or undervalued requires analyzing multiple valuation metrics in context. The stock is currently trading at $0.0411, which is -65% from its 52-week high of $0.12. Investors should consider the broader cannabis industry outlook when forming a valuation opinion. Cannabismarketcap provides all the data needed for a thorough analysis, but this information should not be considered investment advice.

Investing in PharmaCielo (PCLOF) carries several risks that investors should carefully consider. First, the cannabis industry remains federally illegal in the United States, creating regulatory uncertainty that can impact stock prices, banking access, and tax obligations (notably IRC Section 280E). Second, PharmaCielo's cash and debt levels are not reported in our data, so investors should check its latest filings for liquidity and dilution risk. Additionally, the stock has shown a 52-week range of $0.0037 to $0.12, reflecting meaningful price volatility. As with all cannabis stocks, investors face risks from changing state regulations, competitive pressures, and the evolving legal landscape. This information is for educational purposes only and is not investment advice.

PharmaCielo (PCLOF) currently has 188.0M shares outstanding, which when multiplied by the current stock price of $0.0411 gives the company its market capitalization of $7.5M. Share count is important because all per-share metrics (earnings per share, book value per share, etc.) are directly impacted by changes in shares outstanding. Cannabis companies frequently issue new shares to raise capital, so monitoring dilution trends on Cannabismarketcap is recommended for long-term investors.

Most cannabis companies, including PharmaCielo (PCLOF), do not currently pay dividends. The cannabis industry is still in a growth phase, and companies typically reinvest available capital into expanding operations, securing new licenses, building out retail and cultivation infrastructure, and navigating complex regulatory requirements. Additionally, the IRC Section 280E tax burden significantly reduces the free cash flow available for shareholder distributions. Investors in cannabis stocks should generally expect returns to come from capital appreciation rather than dividend income. If PharmaCielo initiates a dividend in the future, it would be reported in their SEC filings and reflected on Cannabismarketcap.

To research PharmaCielo (PCLOF) before investing, start with the company overview on Cannabismarketcap, which provides current price ($0.0411), market cap ($7.5M), and key financial metrics. Next, review the full financial statements page for quarterly revenue trends, margins, and balance sheet details. Check the analyst ratings page for Wall Street consensus and price targets, and the technical analysis page for chart patterns and momentum indicators. Compare PCLOF against sector peers using the comparison tool to understand relative valuation. Review recent news coverage for regulatory developments or corporate events. Finally, read the investment analysis page for a comprehensive deep-dive. Cannabis investing carries unique risks including federal illegality, regulatory uncertainty, and limited banking access — always conduct thorough due diligence before making any investment decision.

PharmaCielo's market capitalization of $7.5M represents the total market value of all its outstanding shares (188.0M shares multiplied by the current stock price of $0.0411). Market cap is the primary measure investors use to classify companies by size: small-cap companies (under $100M) like PharmaCielo may offer higher growth potential but come with greater risk and lower liquidity. In the cannabis sector, market cap is especially important because it determines index weighting, institutional investment eligibility, and often correlates with the company's operational scale and geographic reach. PharmaCielo currently ranks # among cannabis stocks tracked on Cannabismarketcap.

PharmaCielo (PCLOF), like all cannabis companies, faces significant regulatory risks that investors should understand. At the federal level, cannabis remains a Schedule I controlled substance in the United States, which restricts banking access, prevents standard business expense deductions under IRC Section 280E, and creates legal uncertainty. PharmaCielo is subject to the evolving regulatory landscape across the jurisdictions where it operates. Potential catalysts include federal rescheduling (which could ease 280E burdens), the SAFE Banking Act (which would improve banking access), and individual state legalization events. Conversely, regulatory setbacks such as license moratoriums, increased enforcement, or unfavorable tax policy changes pose downside risks. Investors should monitor legislative developments closely using Cannabismarketcap's news and legalization tracker.